Literature DB >> 4584155

Hydralazine elimination in man.

M M Reidenberg, D Drayer, A L DeMarco, C T Bello.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4584155     DOI: 10.1002/cpt1973146970

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  27 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 3.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

4.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 5.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

6.  Clinical pharmacokinetics of hydrallazine.

Authors:  T Talseth
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

7.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

8.  Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension.

Authors:  M G Bianchetti; K Boehringer; P Weidmann; L Link; H Schiffl; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

9.  Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.

Authors:  R A Ahmad; H J Rogers
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

10.  Studies on hydralazine. II. Elimination rate and steady-state concentration in patients with impaired renal function.

Authors:  T Talseth
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.